Literature DB >> 16455829

C-reactive protein levels and clinically important predictive outcomes in stable COPD patients.

J P de Torres1, E Cordoba-Lanus, C López-Aguilar, M Muros de Fuentes, A Montejo de Garcini, A Aguirre-Jaime, B R Celli, C Casanova.   

Abstract

The aim of this study was to determine the relationship between C-reactive protein (CRP) levels and factors known to predict outcome in stable chronic obstructive pulmonary disease (COPD) patients. The following were studied in 130 stable COPD patients: spirometry, lung volume, arterial oxygen tension (P(a,O2)), dyspnoea, 6-min walk distance (6MWD), body mass index, fat-free mass index, BODE (body mass index, obstruction, dyspnoea and exercise capacity), health-related quality of life, smoking status, the presence of cardiovascular risk factors or disease, corticosteroid use and number of exacerbations in the previous year. CRP levels were measured in these patients and in 65 controls. Using univariate and multivariate analyses, any possible association with the predictors of outcomes was evaluated. CRP levels were higher in COPD patients than in controls (4.1 versus 1.8 mg.L(-1), respectively). Correlation was found with the following variables: forced expiratory volume in one second (FEV1; -0.23), FEV1 % (-0.20), forced vital capacity (FVC; -0.24), FVC % (-0.24), Global Initiative for Chronic Obstructive Lung Disease stage (0.17), BODE (0.17), inspiratory capacity/total lung capacity (-0.20), P(a,O2) (-0.40) and 6MWD (-0.30). Using multivariate analysis, P(a,O2) and 6MWD manifested the strongest negative association with CRP levels. C-reactive protein levels in stable chronic obstructive pulmonary disease patients are best correlated with arterial oxygen tension and 6-min walk distance. This should be considered when C-reactive protein levels are measured in stable chronic obstructive pulmonary disease patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455829     DOI: 10.1183/09031936.06.00109605

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  68 in total

1.  C-reactive protein levels are raised in stable Chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposure.

Authors:  Funda Aksu; Nermin Capan; Kurtuluş Aksu; Ruhsar Ofluoğlu; Sema Canbakan; Bünyamin Yavuz; Kadir Okhan Akin
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  Biomarkers in COPD: time for a deep breath.

Authors:  R A Stockley
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

Review 3.  Inhaled and systemic corticosteroids in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Omar A Minai; Zab Mosenifar
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 4.  Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.

Authors:  Mario Cazzola; Luigino Calzetta; Barbara Rinaldi; Clive Page; Giuseppe Rosano; Paola Rogliani; Maria Gabriella Matera
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 5.  The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases.

Authors:  Tracy J Doyle; Victor Pinto-Plata; Danielle Morse; Bartolome R Celli; Ivan O Rosas
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

6.  Determinants of lung volumes in chronic spinal cord injury.

Authors:  Evan L Stepp; Robert Brown; Carlos G Tun; David R Gagnon; Nitin B Jain; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2008-08       Impact factor: 3.966

7.  Systemic inflammation in chronic obstructive pulmonary disease: a population-based study.

Authors:  Francisco Garcia-Rio; Marc Miravitlles; Joan B Soriano; Luis Muñoz; Enric Duran-Tauleria; Guadalupe Sánchez; Víctor Sobradillo; Julio Ancochea
Journal:  Respir Res       Date:  2010-05-25

Review 8.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

9.  The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings.

Authors:  Javier de Miguel-Díez; Pilar Carrasco-Garrido; Javier Rejas-Gutierrez; Antonio Martín-Centeno; Elena Gobartt-Vázquez; Valentín Hernandez-Barrera; Angel Gil de Miguel; Rodrigo Jimenez-Garcia
Journal:  BMC Cardiovasc Disord       Date:  2010-02-18       Impact factor: 2.298

10.  Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial.

Authors:  Carel R van Wetering; Floortje E van Nooten; Stijn J M Mol; Martine Hoogendoorn; Maureen P M H Rutten-Van Mölken; Annemie M Schols
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.